Results of a phase I–II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Formenti, Silvia C ^a   Golden, Encouse B ^a   Goldberg, Judith D ^b   Li, Xiaochun ^b   Taff, Jessica ^b   Fenton Kerimian, Maria B ^a   Chandrasekhar, Sharanya ^a   Demaria, Sandra ^a   Novik, Yelena ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant treatment; chemo radiation; clinical trial; immunogenic cell death; triple negative breast cancer; tumor infiltrating lymphocytes

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; DEATH; DESQUAMATION; EDEMA; ERYTHEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG INSUFFICIENCY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PAIN; PELVIS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIATION DERMATITIS; SAFETY; THERAPY EFFECT; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; VASCULAR DISEASE;

EID: 85014560540     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1274479     Document Type: Article

References (38)

1. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, et al. Chemotherapy and radiotherapy:cryptic anticancer vaccines. Semin Immunol 2010; 22:113-24; PMID:20403709; http://dx.doi.org/10.1016/j.smim.2010.03.001
2. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
3. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848-50; PMID:17657249; http://dx.doi.org/10.1038/sj.cdd.4402201
4. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
5. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
6. Golden EB, Frances D, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. OncoImmunology 2014; 3:e28518; PMID:25071979; http://dx.doi.org/10.4161/onci.28518
7. Turner N, Tutt A, Ashworth A. A Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 2004; 4:814-9; PMID:15510162; http://dx.doi.org/10.1038/nrc1457
8. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26:2126-32; PMID:17016441; http://dx.doi.org/10.1038/sj.onc.1210014
9. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016; 16:110-20; PMID:26775620; http://dx.doi.org/10.1038/nrc.2015.21
10. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96:1659-68; PMID:15547178; http://dx.doi.org/10.1093/jnci/djh312
11. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
12. Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1 controls homology-directed DNA repair. Mol Cell 1999; 4:511-8; PMID:10549283; http://dx.doi.org/10.1016/S1097-2765(00)80202-6
13. Formenti SC, Preston-Martin S, Haffty BG. BRCA1/2 germline mutations:a marker for radioresistance or radiosensitivity? J Clin Oncol 2000; 18:1159-60; PMID:10694571; http://dx.doi.org/10.1200/jco.2000.18.5.1159
14. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:2181-90; PMID:20351327; http://dx.doi.org/10.1200/JCO.2009.26.2543
15. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix:a systematic review and meta-analysis. Lancet 2001; 358:781-6; PMID:11564482; http://dx.doi.org/10.1016/S0140-6736(01)05965-7
16. Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD. Prone vs supine positioning for breast cancer radiotherapy. JAMA 2012; 308:861-3; PMID:22948692; http://dx.doi.org/10.1001/2012.jama.10759
17. Osa EO, DeWyngaert K, Roses D, Speyer J, Guth A, Axelrod D, Fenton Kerimian M, Goldberg JD, Formenti SC. Prone breast intensity modulated radiation therapy:5-year results. Int J Radiat Oncol Biol Phys 2014; 89:899-906; PMID:24867535; http://dx.doi.org/10.1016/j.ijrobp.2014.03.036
18. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98. J Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx.doi.org/10.1200/JCO.2011.41.0902
19. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III randomized adjuvant breast cancer trials:ECOG 2197 and ECOG 1199. J CLin Oncol 2014; 32:2959-66; PMID:25071121; http://dx.doi.org/10.1200/JCO.2013.55.0491
20. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33:983-91; PMID:25534375; http://dx.doi.org/10.1200/JCO.2014.58.1967
21. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92; PMID:23778140; http://dx.doi.org/10.1172/JCI67428
22. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade:a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
23. Emens, LA, Braiteh, FS, Cassier, P, DeLord, J, Eder, JP, Shen, X, Xiao, Y, Wang, Y, Hedge, PS, Chen, D et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res 2014; 75:Abs PD1-6; http://dx.doi.org/10.1158/1538-7445.SABCS14-PD1-6
24. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
25. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer:clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
26. Steward LT, Gao F, Taylor MA, Margenthaler JA. Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncol Lett 2014; 7:548-52; PMID:24396485; http://dx.doi.org/10.3892/ol.2013.1700
27. Formenti SC, Dunnington G, Uzieli B, Lenz H, Keren-Rosenberg S, Silberman H, Spicer D, Denk M, Leichman G, Groshen S, et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated pre-operatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiation Oncology Biol Phys 1997; 39:1059-68; PMID:9392545; http://dx.doi.org/10.1016/S0360-3016(97)00506-3
28. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, et al. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer:a phase I/II tria. J Clin Oncol 2003; 21:864-70; PMID:12610186; http://dx.doi.org/10.1200/JCO.2003.06.132
29. Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, et al. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer:pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 2010; 124:723-32; PMID:20878462; http://dx.doi.org/10.1007/s10549-010-1181-8
30. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010; 16:681-90; PMID:20068102; http://dx.doi.org/10.1158/1078-0432.CCR-09-1091
31. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response:indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx.doi.org/10.1172/JCI35180
32. Formenti SC, Demaria S. Effects of chemoradiation on tumor-host interactions:the immunologic side. J Clin Oncol 2008; 26:1562-3; PMID:18349411; http://dx.doi.org/10.1200/JCO.2007.15.5499
33. Formenti SC, Demaria S. Local control by radiotherapy:is that all there is? Breast Cancer Res 2008; 10:215; PMID:19014406; http://dx.doi.org/10.1186/bcr2160
34. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. [Erratum appears in J Clin Oncol. 2010 Feb 1;28(4):708]. J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370
35. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
36. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784-95; PMID:20404251; http://dx.doi.org/10.1200/JCO.2009.25.6529
37. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer:recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259-71; PMID:25214542; http://dx.doi.org/10.1093/annonc/mdu450
38. Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol 2015; 26:2429-36; PMID:26387142; http://doi.org/10.1093/annonc/mdv395